GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Celldex Therapeutics
Celldex Therapeutics is a biotech company focused on immunotherapy. Its stock price is driven by news about clinical trials. The chart reflects high volatility and dependence on the results of trials of its drugs for the treatment of rare diseases.
Share prices of companies in the market segment - Pharma immune
Celldex Therapeutics is a biotech company focused on immunotherapy. We classify it as a Pharma-immune company, and the chart below shows the dynamics of this entire cutting-edge segment, where the company's value is driven by news of clinical trials.
Broad Market Index - GURU.Markets
Celldex Therapeutics is a biopharmaceutical company developing antibody-based therapies for the treatment of autoimmune and inflammatory diseases. It is a component of the GURU.Markets index. The chart below shows the market. See how Celldex shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CLDX - Daily change in the company's share price Celldex Therapeutics
The volatility of Celldex, a biopharmaceutical company, is measured by change_co. It reflects sensitivity to the results of clinical trials in the field of immunotherapy. This metric is important for formulas on System.GURU.Markets for analyzing the high-risk biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
Celldex Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with the immunotherapy-focused CLDX helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Celldex is a biopharmaceutical company developing drugs to treat inflammatory and allergic diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess the performance of Celldex shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Celldex Therapeutics
Celldex is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Celldex Therapeutics, Inc. is a biotech company developing targeted immunotherapy drugs. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Celldex is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Celldex Therapeutics
Celldex, a biotech company specializing in the treatment of inflammatory and allergic diseases, has sharp monthly fluctuations reflecting the release of clinical trial data for its drug candidates, a key factor for companies at this stage of development.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Celldex Therapeutics is a biotechnology company focused on developing targeted immunotherapeutic drugs for the treatment of complex diseases, including cancer and allergies. The chart below shows the overall dynamics of the immunotherapy sector, one of the most promising and competitive in modern pharmaceuticals.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Celldex Therapeutics is a biotech company developing antibodies to treat cancer and inflammatory diseases. Its stock price is a rollercoaster of ups and downs, driven by the release of clinical trial data. Market sentiment matters little when a potential new blockbuster is at stake.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Celldex Therapeutics
Shares of Celldex Therapeutics, a biopharmaceutical company focused on immunotherapy, reflect weekly progress in treating complex diseases. Their price movements reflect clinical trial data demonstrating how their drugs can harness the immune system to fight disease.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Immuno-oncology is the cutting edge of cancer treatment. The entire sector's weekly performance depends on scientific discoveries and clinical trial data. The chart illustrates this highly volatile backdrop, as Celldex Therapeutics explores new approaches to activating the immune system.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Celldex Therapeutics develops targeted immunotherapy. Shares of such innovative biotech companies often move independently of the market, responding to scientific data. This chart will help you understand: does Celldex exist in its own world of clinical trials, or does the overall market environment influence its stock price?
Market capitalization of the company, segment and market as a whole
CLDX - Market capitalization of the company Celldex Therapeutics
Celldex's market capitalization tells the story of long and hard work in the field of immunotherapy. Its chart reflects years of research and a recent breakthrough with a drug for the treatment of chronic urticaria. The dynamics tell the story of how one successful program can radically change the valuation of a biotech company.
CLDX - Share of the company's market capitalization Celldex Therapeutics within the market segment - Pharma immune
Celldex Therapeutics is a biotech company developing innovative antibody-based therapies for the treatment of autoimmune and other severe diseases. Its market share reflects the potential of its leading candidates. The chart tells a story of scientific perseverance and hope for new therapeutic breakthroughs.
Market capitalization of the market segment - Pharma immune
Celldex Therapeutics is a biotech company developing innovative antibody-based drugs. The chart below shows the overall market capitalization of this sector. Its volatile dynamics reflect the long and risky journey from the lab to the market, where every clinical trial result can dramatically change the company's valuation.
Market capitalization of all companies included in a broad market index - GURU.Markets
Celldex Therapeutics develops immunotherapeutic drugs for the treatment of cancer and allergic diseases. Its market capitalization is based on the potential of its antibody-targeted therapies. The chart below shows the economic weight of the immunotherapy sector.
Book value capitalization of the company, segment and market as a whole
CLDX - Book value capitalization of the company Celldex Therapeutics
Celldex Therapeutics' balance sheet represents its capital invested in clinical trials of innovative immunotherapeutic drugs targeting difficult-to-treat diseases. This is a tangible, scientific foundation built on years of research. How has this biotech asset changed? The chart below shows its dynamics.
CLDX - Share of the company's book capitalization Celldex Therapeutics within the market segment - Pharma immune
Celldex Therapeutics works in the field of immunotherapy, developing antibodies in its laboratories. The chart shows the share of these research assets in the sector, reflecting the physical foundation upon which the company is developing new approaches to treating cancer and other diseases.
Market segment balance sheet capitalization - Pharma immune
Immuno-oncology, as the BCap_Seg chart for biotech shows, is a knowledge-intensive industry. Celldex Therapeutics operates in this environment, where its assets are not factories, but a portfolio of patents and clinical trial data. Its capital is invested in science, not in manufacturing infrastructure at this stage.
Book value of all companies included in the broad market index - GURU.Markets
Celldex Therapeutics' assets include cutting-edge laboratories and intellectual property in the field of immunotherapy. The company's book value reflects the capital invested in its scientific infrastructure, which serves as a launchpad for the development of a new generation of drugs targeting complex diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Celldex Therapeutics
Celldex Therapeutics is another immuno-oncology company. Its value lies not in its lab equipment, but in its pipeline of experimental drugs. The MvsBCap ratio shows how investors assess the likelihood of one of these drugs becoming a successful treatment. The graph visualizes the hopes and risks inherent in biotechnology.
Market to book capitalization ratio in a market segment - Pharma immune
Celldex Therapeutics is a biotech company focused on immunotherapy. Its valuation is based almost entirely on the prospects of its scientific developments. This chart shows how investors assess the potential of its drug candidates, which is significantly higher than its tangible assets.
Market to book capitalization ratio for the market as a whole
Celldex Therapeutics develops immunotherapeutic drugs. Its value is determined by its pipeline and hopes for success in clinical trials. This is a classic example of how, in the biotech sector, market capitalization reflects future potential rather than current tangible assets, which contrasts sharply with the market average.
Debts of the company, segment and market as a whole
CLDX - Company debts Celldex Therapeutics
Celldex Therapeutics, a biopharmaceutical company focused on immunotherapy, uses its raised funds to advance its drug candidates through clinical trials. Prior to commercialization, the company relies entirely on investor confidence. This chart shows the company's financial journey in its quest to develop new treatments for complex diseases.
Market segment debts - Pharma immune
Celldex Therapeutics focuses on developing immunotherapeutic drugs for the treatment of oncology and allergic diseases. For a research-stage biotech company, capital structure is crucial. This chart shows how Celldex funds its research and how its approach compares to other players in the sector.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Celldex Therapeutics
Celldex Therapeutics is a biopharmaceutical company focused on immunotherapy. The chart shows how it finances its research. For a company in clinical development and without stable revenue, any debt is a high-risk factor. Its presence and size reflect creditors' faith in the potential of its drugs.
Market segment debt to market segment book capitalization - Pharma immune
Celldex Therapeutics is an immuno-oncology company operating at the forefront of science. This biotech chart illustrates investors' appetite for risk and funding expensive research. It helps us understand how the company's financial position is typical for an industry where the stakes and potential rewards are extremely high.
Debt to book value of all companies in the market
Celldex Therapeutics is a biotech company operating at the cutting edge of science. This chart reflects the overall risk appetite in the economy. For a company burning capital for future discoveries, it helps understand how its risky funding model compares to the overall market conditions and investors' willingness to wait.
P/E of the company, segment and market as a whole
P/E - Celldex Therapeutics
The chart for Celldex Therapeutics, an immunotherapy company, shows how investors value its research. The high values reflect not so much current profits as hopes that its experimental drugs will prove effective and find a niche in the vast market for autoimmune and oncological treatments.
P/E of the market segment - Pharma immune
This chart shows the average P/E for the immuno-oncology sector, where Celldex Therapeutics operates. The industry's very high average valuation suggests high investor expectations. The chart illustrates this general backdrop against which the risks and potential of Celldex's specific developments are assessed.
P/E of the market as a whole
Celldex Therapeutics focuses on developing innovative immunotherapeutic drugs for the treatment of oncology and allergic diseases. The company operates at the cutting edge of science. Given the overall sentiment in the biotech sector, which can be compared with this chart, Celldex's valuation reflects investors' faith in the potential of its unique scientific approach.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Celldex Therapeutics
Celldex Therapeutics is a biotechnology company focused on developing therapeutic antibodies for the treatment of autoimmune and allergic diseases. The chart reflects future revenue expectations, which are entirely dependent on the success of its clinical trials and the market potential of its drug candidates.
%20P%2FE%20Celldex%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Celldex-Therapeutics&v=1772513511976 "Chart of the company's future (projected) P/E Celldex Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Celldex Therapeutics focuses on developing therapeutic antibodies for the treatment of autoimmune diseases and oncology. The company is in clinical trials. The chart reflects future revenue expectations for the sector. It helps understand how optimistic the market is about its leading drug candidates and their commercial potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513511996 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Celldex Therapeutics is a biotech company focused on developing immunotherapeutic drugs for the treatment of cancer and allergies. Its prospects depend on scientific breakthroughs. This overall risk appetite chart is an indicator of the market's willingness to fund innovative, yet risky, approaches to medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513512007 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Celldex Therapeutics
Celldex Therapeutics is a biotech company developing immunotherapeutic drugs, primarily for the treatment of inflammatory diseases and oncology. Financial metrics reflect clinical trial expenses. This chart illustrates the long-term investment cycle in biotech, where today's expenses are the basis for future revenue.
Profit of companies in the market segment - Pharma immune
Celldex Therapeutics is a biopharmaceutical company focused on developing immunotherapeutic drugs and antibodies for the treatment of cancer and other complex diseases. This chart reflects the overall profitability of the immunotherapy sector, which is one of the most promising in modern medicine and attracts significant investment.
Overall market profit
Celldex Therapeutics is a biotechnology company developing immunotherapeutic drugs. Its value and prospects depend solely on the success of its clinical trials and the potential of its scientific developments. The overall economic situation, illustrated by this chart, has no direct impact on the company's scientific process or intrinsic value.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Celldex Therapeutics
Celldex Therapeutics is a biotechnology company focused on developing therapeutic antibodies for the treatment of cancer and allergic diseases. Future profits depend on the results of clinical trials. This chart shows analysts' speculative expectations regarding the success of its scientific developments and the potential to become a leader in its niche.
%20profit%20of%20the%20company%20Celldex%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Celldex-Therapeutics&v=1772513512099 "Graph of future (projected) profit of the company Celldex Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Celldex Therapeutics is a biotechnology company focused on developing immunotherapeutic drugs for the treatment of difficult-to-treat diseases, including cancer and allergies. Its future depends on the success of clinical trials. This chart shows revenue projections for the immunopharmaceuticals sector, providing context for evaluating Celldex's innovative platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513512135 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Celldex Therapeutics is a biotechnology company developing immunotherapeutic drugs. Its success is determined by clinical trial results. Market sentiment, indirectly reflected by this revenue expectation graph, influences the availability of funding for development-stage companies like Celldex.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513512211 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Celldex Therapeutics
Celldex Therapeutics is a biotech company focused on immunotherapy and the treatment of inflammatory diseases. Revenue is minimal at the clinical stage. This graph reflects investors' faith in the company's science. Any changes to it are a reaction to clinical trial data, which could make or break future revenue streams.
P/S market segment - Pharma immune
Celldex Therapeutics is a biotechnology company developing therapeutic antibodies for the treatment of severe diseases, including autoimmune diseases and cancer. Their focus on innovative mechanisms of action may lead to breakthrough drugs. This chart reflects the average revenue estimate for the sector, which helps assess Celldex's scientific potential.
P/S of the market as a whole
Celldex Therapeutics is a biotech company developing immunotherapeutic drugs for the treatment of cancer and other difficult-to-treat diseases. The company's valuation is based on expectations for its R&D. This chart helps explain why the valuation of such innovative companies can differ significantly from the average market, where revenue plays a key role.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Celldex Therapeutics
Celldex Therapeutics is a biotechnology company focused on developing targeted antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's clinical-stage revenue estimates reflect investor confidence. This chart shows the market's confidence in Celldex's scientific approach and the commercial potential of its lead drug candidates.
%20P%2FS%20Celldex%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Celldex-Therapeutics&v=1772513512463 "The graph of the company's future (projected) P/S Celldex Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Celldex Therapeutics is a biotech company focused on developing targeted antibody therapies for the treatment of autoimmune and other severe diseases. This chart reflects how investors assess the company's future revenues relative to the pharmaceutical sector. It demonstrates the market's confidence in the potential of its leading drug candidates and their ability to successfully complete clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513512496 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Celldex Therapeutics develops targeted immunotherapy. It's a science-intensive business whose full potential may be realized within a few years. Revenue growth expectations, as shown in the graph, don't always take into account potential breakthroughs in biotech that could radically change the healthcare landscape.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513512525 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Celldex Therapeutics
This chart shows the revenue of Celldex Therapeutics, a biotech company focused on developing targeted immunotherapies for difficult-to-treat diseases. Because its drugs are in clinical trials, revenue may be zero or comprised of affiliate fees. The trend reflects progress in research and development.
Sales of companies in the market segment - Pharma immune
Celldex Therapeutics develops innovative antibody-based therapies for cancer and allergic diseases. Being in the clinical stage, the company does not yet have stable sales revenue. Its potential future revenue structure will depend on which of its promising drugs is first to market.
Overall market sales
Celldex Therapeutics is a biotech company developing innovative immunotherapeutic drugs. Its trajectory is entirely dependent on research results and the potential of its scientific discoveries. This chart, reflecting the pulse of the consumer economy, reveals little about Celldex's prospects for combating serious diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Celldex Therapeutics
Celldex Therapeutics is a biotechnology company focused on developing immunotherapeutic drugs for the treatment of oncology and allergic diseases. Future revenue depends on the success of its clinical programs and potential partnerships. This chart reflects analyst expectations for the commercial potential of its lead drug candidates if approved.
%20sales%20of%20the%20company%20Celldex%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Celldex-Therapeutics&v=1772513512679 "Schedule of future (projected) sales of the company Celldex Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Celldex Therapeutics is a biotechnology company focused on developing therapeutic antibodies and immunomodulators. This chart shows the outlook for the immunotherapy sector. Is further growth expected in this promising market thanks to new scientific discoveries? This helps assess the overall potential of Celldex's field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513512756 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Celldex Therapeutics is a biotechnology company focused on developing immunotherapeutic drugs. Its value and prospects depend entirely on clinical trial data and the potential of its research. This chart, which reflects macroeconomic trends, has no direct bearing on the likelihood of its drugs being successful in treating diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513512788 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Celldex Therapeutics
Celldex Therapeutics is a biotechnology company focused on developing therapeutic antibodies and other immune modulators for the treatment of cancer and allergic diseases. This chart reflects its financial performance during the research phase. Profitability is a future projection, dependent on successful clinical trials and the potential commercialization of new drugs.
Market segment marginality - Pharma immune
Celldex Therapeutics is a biotechnology company developing immunotherapeutic drugs for the treatment of cancer and other serious diseases. The company is in the clinical stage, which means it is investing heavily in research. This metric reflects its current financial performance, with future profitability dependent on the successful commercialization of its research.
Market marginality as a whole
Celldex Therapeutics, a developer of immunotherapeutic drugs, is at the forefront of the fight against cancer and other diseases. Its growth depends on long-term research funding. This total return chart reflects the investment climate, which determines the market's willingness to invest in high-risk biotech companies.
Employees in the company, segment and market as a whole
Number of employees in the company Celldex Therapeutics
Celldex Therapeutics is a biotech company developing targeted antibody-based therapies. Its team consists of scientists and clinicians who advance these drugs through clinical trials. This chart shows how the company is ramping up its resources as its lead candidates show encouraging results and move into later, more expensive phases of research.
Share of the company's employees Celldex Therapeutics within the market segment - Pharma immune
Celldex Therapeutics is a biotechnology company focused on developing immunotherapeutic drugs for the treatment of cancer and other complex diseases. Its staff consists primarily of scientists and clinical research specialists. This chart shows the company's market share, reflecting its scale in the R&D sector and the competition for scientific talent.
Number of employees in the market segment - Pharma immune
Celldex Therapeutics develops targeted immunotherapies for the treatment of difficult-to-treat diseases, including cancer. This chart shows employment in the immunopharmaceutical sector. The rapid growth in the number of specialists here demonstrates the significant potential and investment in harnessing the immune system to fight disease, which is at the core of Celldex's strategy.
Number of employees in the market as a whole
Celldex Therapeutics is a biotech company developing immunotherapy and targeted therapies. Its staff consists of highly qualified scientists. The team's growth, compared to the overall employment in this chart, speaks not to the state of the economy, but to progress in clinical trials and investor confidence in the company's scientific platform.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Celldex Therapeutics (CLDX)
Celldex Therapeutics is a biotech company developing immunotherapy. This chart is a clear example of how the market values science. All value can be concentrated in a few promising molecules. The astronomical market capitalization per employee reflects not current revenue, but investors' faith in future breakthrough drugs.
%20of%20the%20company%20Celldex%20Therapeutics%20(CLDX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Celldex-Therapeutics-CLDX&v=1772513513146 "Chart of market capitalization per employee (in thousands of dollars) of the company Celldex Therapeutics (CLDX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Celldex Therapeutics (CLDX) is a clinical-stage biotech company specializing in the development of antibodies for the treatment of inflammatory and allergic diseases. This chart shows the industry average cost per employee. It helps assess how the market values their R&D portfolio and scientific team per employee.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513513177 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Celldex Therapeutics is a biotech company focused on immunotherapy and autoimmune disease treatment. Its market capitalization is based on the potential of its R&D pipeline. The high valuation per employee on this chart reflects investor expectations regarding the potential breakthroughs the company's scientific team can achieve.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513513198 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Celldex Therapeutics (CLDX)
Celldex is a clinical-stage biotech company working in immunotherapy. Like many biotechs without stable sales, this graph likely shows a negative value. It shows how much the company is investing in each of its scientists and researchers in hopes of a future blockbuster. This is an indicator of R&D workload.
%20Chart%20Celldex%20Therapeutics%20(CLDX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Celldex-Therapeutics-CLDX&v=1772513513225 "Company Profit Per Employee (in thousands of dollars) Chart Celldex Therapeutics (CLDX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Celldex (CLDX) is a biotech R&D (immunology) benchmark. This chart shows the benchmark for "Immune Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513513252 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Celldex Therapeutics is a clinical-stage biotech company specializing in immunology (e.g., chronic urticaria). It's an R&D business. Like other biopharmas without products, this chart shows the operating loss per employee—the "cost" of conducting expensive clinical trials per research staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513513302 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Celldex Therapeutics (CLDX)
Celldex Therapeutics is a biotech company working in the field of immunotherapy. This figure may be negligible during the research phase. However, it represents future potential: if their drugs are approved, revenue per employee could skyrocket, demonstrating the enormous value of their intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Celldex-Therapeutics-CLDX&v=1772513513320 "Sales chart per company employee Celldex Therapeutics (CLDX)")
Sales per employee in the market segment - Pharma immune
Celldex Therapeutics is a biotech company working on immunotherapy and targeted drugs for the treatment of oncology and autoimmune diseases. This is pure R&D. This chart shows the average output in the sector. For CLDX, which is in clinical trials, this is more of a leading indicator of personnel costs compared to the potential of their developments.
Sales per employee for the market as a whole
Celldex Therapeutics is a biotech company focused on immunotherapy and rare disease treatment. Like many R&D companies, they may have minimal revenue before a drug is approved. This chart illustrates the "cost" of research: the company spends resources on its team of scientists in the hopes of future commercial success.
Short shares by company, segment and market as a whole
Shares shorted by company Celldex Therapeutics (CLDX)
Celldex (CLDX) is a biotech company focused on immunotherapy, specifically for the treatment of chronic skin diseases. This chart shows the volume of short positions. High short positions are typical for biotechs and reflect investors' bets that clinical trials of key drug candidates will not yield the expected positive results.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Celldex-Therapeutics-CLDX&v=1772513513365 "Short Shares Chart for the Company Celldex Therapeutics (CLDX)")
Shares shorted by market segment - Pharma immune
Celldex Therapeutics (CLDX) is a biotech company specializing in immunotherapy, specifically the treatment of inflammatory and allergic diseases (chronic urticaria). This chart shows the total short position in the immunopharmaceuticals sector, reflecting investor concerns about the high level of competition in this field.
Shares shorted by the overall market
Celldex (CLDX) is a clinical-stage biotech (immunology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives CLDX of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Celldex Therapeutics (CLDX)
Celldex Therapeutics (CLDX) is a biotech company developing innovative antibody-based therapies for patients with severe inflammatory diseases and cancer. Their value lies in their R&D pipeline. This chart measures hype. It shows when positive trial data leads to "overbought" (above 70) or when delays lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Celldex-Therapeutics-CLDX&v=1772513513449 "RSI 14 indicator chart for the company's stock Celldex Therapeutics (CLDX)")
RSI 14 Market Segment - Pharma immune
Celldex (CLDX) is a biotech company developing antibodies to treat complex immune diseases (such as hives). The RSI_14_Seg for "Pharma immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether CLDX's growth is due to its R&D or simply general hype in the sector.
RSI 14 for the overall market
Celldex (CLDX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CLDX (Celldex Therapeutics)
Celldex Therapeutics is a biotech company focused on developing antibodies for the treatment of autoimmune and allergic diseases. Its lead candidate targets chronic urticaria. This chart reflects analyst consensus. Their target prices are based on the drug's potential success in clinical trials and an assessment of its market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CLDX-Celldex-Therapeutics&v=1772513513526 "A chart showing analyst consensus forecasts for the expected stock price. CLDX (Celldex Therapeutics)")
The difference between the consensus estimate and the actual stock price CLDX (Celldex Therapeutics)
Celldex Therapeutics is a biotech company focused on immunology. Their flagship product is Barzolvolimab, an antibody for the treatment of hives and other mast cell diseases. This chart reflects analysts' high expectations for their lead drug candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CLDX-Celldex-Therapeutics&v=1772513513546 "A chart showing the difference between the consensus forecast and the actual stock price. CLDX (Celldex Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Celldex Therapeutics is a clinical-stage biotech company developing targeted therapies for the treatment of severe inflammatory and allergic diseases. This chart shows analysts' overall expectations for the immune pharma sector. It reflects whether experts believe in the potential of their lead drug, barisolimab.
Analysts' consensus forecast for the overall market share price
Celldex Therapeutics is a biotech company specializing in immunotherapy, specifically the treatment of chronic urticaria and other inflammatory diseases. This chart shows overall market sentiment. For Celldex, as for any biotech, it's important to understand how these expectations (risk appetite) influence the valuation of their development pipeline and investor willingness to wait for results. (347)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Celldex Therapeutics
Celldex (CLDX) is a clinical-stage biotech focused on treating inflammatory and immune diseases, particularly chronic urticaria. This chart represents pure R&D value. Its valuation is not tied to current revenue but reflects investors' faith in their lead drug and its potential in this large and competitive market niche.
AKIMA Market Segment Index - Pharma immune
Celldex (CLDX) is a clinical-stage biotech focused on immunology; after some setbacks, the company is focusing on a new candidate (Barzolvolimab) for the treatment of chronic urticaria. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this new R&D focus (CLDX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Celldex is a biotech company developing antibody-based therapies for the treatment of inflammatory, allergic, and autoimmune diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative story, fueled by clinical trial data, compares to overall economic trends.
